Skip to main content
Erschienen in: Cancer Causes & Control 6/2014

01.06.2014 | Original paper

Moderate alcohol intake and cancer: the role of underreporting

verfasst von: Arthur L. Klatsky, Natalia Udaltsova, Yan Li, David Baer, H. Nicole Tran, Gary D. Friedman

Erschienen in: Cancer Causes & Control | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is compelling evidence that heavy alcohol drinking is related to increased risk of several cancer types, but the relationship of light–moderate drinking is less clear. We explored the role of inferred underreporting among light–moderate drinkers on the association between alcohol intake and cancer risk.

Methods

In a cohort of 127,176 persons, we studied risk of any cancer, a composite of five alcohol-associated cancer types, and female breast cancer. Alcohol intake was reported at baseline health examinations, and 14,880 persons were subsequently diagnosed with cancer. Cox proportional hazard models were controlled for seven covariates. Based on other computer-stored information about alcohol habits, we stratified subjects into 18.4 % (23,363) suspected of underreporting, 46.5 % (59,173) not suspected of underreporting, and 35.1 % (44,640) of unsure underreporting status.

Results

Persons reporting light–moderate drinking had increased cancer risk in this cohort. For example, the hazard ratios (95 % confidence intervals) for risk of any cancer were 1.10 (1.04–1.17) at <1 drink per day and 1.15 (1.08–1.23) at 1–2 drinks per day. Increased risk of cancer was concentrated in the stratum suspected of underreporting. For example, among persons reporting 1–2 drinks per day risk of any cancer was 1.33 (1.21–1.45) among those suspected of underreporting, 0.98 (0.87–1.09) among those not suspected, and 1.20 (1.10–1.31) among those of unsure status. These disparities were similar for the alcohol-related composite and for breast cancer.

Conclusions

We conclude that the apparent increased risk of cancer among light–moderate drinkers may be substantially due to underreporting of intake.
Literatur
1.
Zurück zum Zitat Bagnardi V, Rota M, Botteri E, Tramaceri I, Islami F, Fedente V et al (2013) Light alcohol drinking and cancer: a meta-analysis. Ann Oncol 2:701–708 Bagnardi V, Rota M, Botteri E, Tramaceri I, Islami F, Fedente V et al (2013) Light alcohol drinking and cancer: a meta-analysis. Ann Oncol 2:701–708
2.
Zurück zum Zitat Jin M, Cai S, Guo J, Zhu Y, Li M, Yu Y et al (2013) Alcohol drinking and all cancer mortality: a meta-analysis. Ann Oncol 3:807–816CrossRef Jin M, Cai S, Guo J, Zhu Y, Li M, Yu Y et al (2013) Alcohol drinking and all cancer mortality: a meta-analysis. Ann Oncol 3:807–816CrossRef
3.
Zurück zum Zitat Li Y, Baer D, Friedman GD, Udaltsova N, Shim V, Klatsky AL (2008) Wine, liquor, beer and risk of breast cancer in a large population. Eur J Cancer 45(5):843–850PubMedCrossRef Li Y, Baer D, Friedman GD, Udaltsova N, Shim V, Klatsky AL (2008) Wine, liquor, beer and risk of breast cancer in a large population. Eur J Cancer 45(5):843–850PubMedCrossRef
4.
Zurück zum Zitat Seitz HK, Pelucchi C, Bagnardi V, La Vecchia C (2012) Epidemiology and pathophysiology of alcohol and breast cancer: update 2012. Alcohol Alcohol 47(3):204–212PubMedCrossRef Seitz HK, Pelucchi C, Bagnardi V, La Vecchia C (2012) Epidemiology and pathophysiology of alcohol and breast cancer: update 2012. Alcohol Alcohol 47(3):204–212PubMedCrossRef
5.
Zurück zum Zitat Winstanley MH, Pratt IS, Chapman K, Griffin HJ, Croager ST, Olver IN et al (2011) Alcohol and cancer: a position statement from Cancer Council Australia. Med J Aust 194(9):479–482PubMed Winstanley MH, Pratt IS, Chapman K, Griffin HJ, Croager ST, Olver IN et al (2011) Alcohol and cancer: a position statement from Cancer Council Australia. Med J Aust 194(9):479–482PubMed
6.
Zurück zum Zitat Nelson DE, Jarman DW, Rehm J, Greenfield TK, Rey G, Kerr WC et al (2013) Alcohol-attributable cancer deaths and years of potential life lost in the United states. Am J Public Health 103(4):641–648PubMedCentralPubMedCrossRef Nelson DE, Jarman DW, Rehm J, Greenfield TK, Rey G, Kerr WC et al (2013) Alcohol-attributable cancer deaths and years of potential life lost in the United states. Am J Public Health 103(4):641–648PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A et al (2009) Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst 101(5):296–305PubMedCrossRef Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A et al (2009) Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst 101(5):296–305PubMedCrossRef
8.
Zurück zum Zitat Klatsky AL (1994) Epidemiology of coronary heart disease—influence of alcohol. Alcohol Clin Exp Res 18(1):88–96PubMedCrossRef Klatsky AL (1994) Epidemiology of coronary heart disease—influence of alcohol. Alcohol Clin Exp Res 18(1):88–96PubMedCrossRef
9.
Zurück zum Zitat Klatsky AL (1999) [Editorial]. Is it the drink or the drinker? Circumstantial evidence only raises a probability. Editorial. Am J Clin Nutr 69(1):2–3PubMed Klatsky AL (1999) [Editorial]. Is it the drink or the drinker? Circumstantial evidence only raises a probability. Editorial. Am J Clin Nutr 69(1):2–3PubMed
10.
Zurück zum Zitat Klatsky AL, Gunderson E, D G, Kipp H, Udaltsova N, Friedman GD (2006) Higher prevalence of systemic HTN among moderate alcohol drinkers: exploring the role of under-reporting. J Stud Alcohol 67(3):421–428PubMed Klatsky AL, Gunderson E, D G, Kipp H, Udaltsova N, Friedman GD (2006) Higher prevalence of systemic HTN among moderate alcohol drinkers: exploring the role of under-reporting. J Stud Alcohol 67(3):421–428PubMed
11.
Zurück zum Zitat Klatsky AL, Udaltsova N (2013) Commentary. Abounding confounding. Addiction 108(9):1549–1552PubMedCrossRef Klatsky AL, Udaltsova N (2013) Commentary. Abounding confounding. Addiction 108(9):1549–1552PubMedCrossRef
12.
Zurück zum Zitat Collen MF, Davis LF (1969) The multitest laboratory in health care. J Occup Med 11(7):355–360PubMed Collen MF, Davis LF (1969) The multitest laboratory in health care. J Occup Med 11(7):355–360PubMed
13.
Zurück zum Zitat Tran HN, Li Y, Siu D, Baer D, Friedman GD, Udaltsova N, Klatsky AL (2013) Predictors of lung cancer: noteworthy cell type differences. Perm J 17(2):23–29PubMedCentralPubMedCrossRef Tran HN, Li Y, Siu D, Baer D, Friedman GD, Udaltsova N, Klatsky AL (2013) Predictors of lung cancer: noteworthy cell type differences. Perm J 17(2):23–29PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Klatsky AL, Armstrong MA, Landy C, Udaltsova N (2003) The effect of coronary disease on changes in drinking in an older population. Alcohol Res 8:211–213 Klatsky AL, Armstrong MA, Landy C, Udaltsova N (2003) The effect of coronary disease on changes in drinking in an older population. Alcohol Res 8:211–213
15.
Zurück zum Zitat Klatsky AL, Armstrong MA, Kipp H (1990) Correlates of alcoholic beverage preference: traits of persons who choose wine, liquor, or beer. Br J Addict 85(10):1279–1289PubMedCrossRef Klatsky AL, Armstrong MA, Kipp H (1990) Correlates of alcoholic beverage preference: traits of persons who choose wine, liquor, or beer. Br J Addict 85(10):1279–1289PubMedCrossRef
16.
Zurück zum Zitat Friedman GD, Klatsky AL (1994) Is alcohol good for your health? [Editorial]. N Engl J Med 329(25):1882–1883CrossRef Friedman GD, Klatsky AL (1994) Is alcohol good for your health? [Editorial]. N Engl J Med 329(25):1882–1883CrossRef
Metadaten
Titel
Moderate alcohol intake and cancer: the role of underreporting
verfasst von
Arthur L. Klatsky
Natalia Udaltsova
Yan Li
David Baer
H. Nicole Tran
Gary D. Friedman
Publikationsdatum
01.06.2014
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 6/2014
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0372-8

Weitere Artikel der Ausgabe 6/2014

Cancer Causes & Control 6/2014 Zur Ausgabe

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.